EPISODE · Apr 28, 2026 · 30 MIN
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
from BioCentury This Week · host BioCentury
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates.The analysts also discuss Eli Lilly's latest deal — for a JAK-2 inhibitor from Ajax — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners’ new venture fund and the latest in BioCentury’s Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company Elevara Medicines. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.View full story: https://www.biocentury.com/article/659298#AACR #OncologyTargets #Immunotherapy #BiotechMA #ADC00:01 - Sponsor Message: IQVIA Biotech02:50 - AACR: New Targets11:08 - AACR: Pan-RAS Inhibitor ADCs15:35 - Biopharma Deals23:53 - Kurma's New Venture Fund27:28 - Emerging Company Profile: ElevaraTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
What this episode covers
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates. The analysts also discuss Eli...
NOW PLAYING
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m